Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study is a prospective, single-arm, phase 2 clinical trial assessing the feasibility, efficacy, and safety of the PD-L1 inhibitor Benmelstobart (TQB2450) as an adjuvant therapy regimen in patients with pathologic stage IB, IASLC grade 3 invasive lung adenocarcinoma without EGFR active mutations or ALK rearrangement.
Epistemonikos ID: ec15535745babd67ba2d96b12c3bb17af50d5498
First added on: Aug 01, 2024